Results 1 to 10 of about 53,199 (230)

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma [PDF]

Haematologica, 2015
Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos, Robert Z. Orlowski, Thierry Facon, Pieter Sonneveld, Kenneth C. Anderson, Meral Beksac, Lotfi Benboubker, Huw Roddie, Anna Potamianou, Catherine Couturier, Huaibao Feng, Ozlem Ataman, Helgi van de Velde, Paul G. Richardson   +13 more
doaj   +7 more sources

Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice [PDF]

Journal of Neuroinflammation
Background Peripheral neuropathy and gastrointestinal dysfunction are frequent, debilitating side effects of the neurotoxic myeloma drug bortezomib that reduce quality of life and adherence to optimal therapy.
Jacqui S. Scott, Sadia Munir, Miriam A. Lynn, Jvaughn A. Duggan, Joel Castro, Andrea M. Harrington, Stuart M. Brierley, Gudrun Schober, Kathy Cash, Bernice Gutschmidt, Mark R. Hutchinson, Angelina Yong, Samuel P. Costello, Suranjana Sikdar, Pawanrat Tangseefa, Duncan R. Hewett, Courtney B. Cross, Susanna B. Park, Feargal J. Ryan, Andrew C. W. Zannettino, David J. Lynn, Kate Vandyke, Hannah R. Wardill, Krzysztof M. Mrozik   +23 more
doaj   +2 more sources

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Protein and Cell, 2018
Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Zhen Cai, Xi Huang, Jingsong He
exaly   +3 more sources

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Buket Alpertunga, Maria Fedorova, Kazim Yalcin Arga   +2 more
exaly   +3 more sources

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]

PLoS ONE, 2013
Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu, Duen-Ren Hou, Chun-Yu Liu, Chen-Si Lin, Chung-Wai Shiau, Ann-Lii Cheng, Kuen-Feng Chen   +6 more
doaj   +1 more source

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib

Molecules, 2023
Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the possibility of interaction between bortezomib and cellular components ...
Mihaela-Cristina Bunea, Teodor Adrian Enache, Victor Constantin Diculescu   +2 more
doaj   +1 more source

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Neoplasia: An International Journal for Oncology Research, 2022
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson   +12 more
doaj   +1 more source

Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. [PDF]

PLoS ONE, 2013
Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored.
Julia S Gelman, Juan Sironi, Iryna Berezniuk, Sayani Dasgupta, Leandro M Castro, Fabio C Gozzo, Emer S Ferro, Lloyd D Fricker   +7 more
doaj   +1 more source

Treatment Outcomes with Reduced-Dose Bortezomib in Adult Patients with Multiple Myeloma: A Single-Center Experience

Asian Journal of Oncology, 2022
Objectives Bortezomib vial-sharing is commonly employed to maximize the treatment of patients with multiple myeloma (MM) in resource-limited setting. This strategy minimizes delays in treatment but reduces the dose of bortezomib received by the patient ...
Jeremiah R. Vallente, Carlo Francisco N. Cortez, Ma Angelina L. Mirasol   +2 more
doaj   +1 more source

Characterization of bortezomib-adapted I-45 mesothelioma cells

Molecular Cancer, 2010
Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander, Cao Xiaobo, Cui Yu, Littlejohn James E, Zhang Lidong, Smythe W Roy   +5 more
doaj   +1 more source